Skip to Content

Clinical Trial Details

USOR 13033

Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer

Purpose/Objective

Request Additional Trial Information
Full Trial Details: ClinicalTrials.gov

Condition: Breast Cancer
Study Type: Interventional
Phase: Phase II
Study Start Date: 07/06/2014
Study Completion Date: TBD
Additional Location(s): Washington Adventist Hospital

The goal of this clinical research study is to learn if the study drug, alisertib, in combination with chemotherapy (paclitaxel), can shrink or slow tumor growth in women with hormone receptor (HR)-positive, HER2-negative or HR-negative, HER2-negative (triple negative) locally recurrent or metastatic breast cancer. The safety of alisertib in combination with paclitaxel will also be studied. The physical state of the patient, symptoms, changes in the size of the tumor, and laboratory findings obtained while on-study will help the research team decide if alisertib plus paclitaxel is safe and effective in patients with this type of breast cancer.

NCT Number
NCT02187991
Principal Investigator(s)
Cheryl A. Aylesworth, MD
Sponsor(s)
US Oncology Research
Participant Eligibility
  • Age: 18 - No Maximum
  • Gender: Female

Location

  • Shady Grove Adventist Aquilino Cancer Center
    9905 Medical Center Drive
    Rockville, MD 20850
    Main: 240-826-6297

Clincal Trials & Research Studies

Patient Stories

We’re writing new chapters in the lives of our patients, their families and our community daily. These are their stories:

Local Health News - In Your Inbox

Join over 40k of your friends & neighbors and get the latest news about community health programs and events when you sign-up for Adventist HealthCare & You Digital.

Subscribe Today!